Author

M. V. Filsinger Interrante

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:CRISPR screen· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. A. Rubio· 2 shared B. N. Bell· 2 shared C. C. LaBranche· 2 shared D. C. Montefiori· 2 shared P. S. Kim· 2 shared A. M. Dudek· 1 shared A. S. Valdez· 1 shared B. J. Lesch· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. A. Rubio

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Combining Cell-Intrinsic and -Extrinsic Resistance to HIV-1 By Engineering Hematopoietic Stem Cells for CCR5 Knockout and B Cell Secretion of Therapeutic Antibodies

W. N. Feist, S. E. Luna, K. Ben-Efraim, M. V. Filsinger Interrante, N. A. Amorin, N. M. Johnston, T. U. J. Bruun, H. Y. Ghanim, B. J. Lesch, A. M. Dudek, M. H. Porteus

This paper describes engineering hematopoietic stem cells to produce CCR5 knockout cells and secrete HIV-1 inhibiting antibodies, aiming for a one-time cure for HIV-1.

bioRxiv · Mar 8, 2024 · PreprintBioengineering

Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Drive Distinct Immune Signatures and Potent Vaccine Responses

B. S. Ou, J. Baillet, M. V. Filsinger Interrante, J. Z. Adamska, X. Zhou, O. Saouaf, J. Yan, J. Klich, C. K. Jons, E. Meany, A. S. Valdez, L. Carter, B. Pulendran, N. P. King, E. Appel

This paper develops a modular saponin-based nanoparticle adjuvant platform incorporating TLR agonists, showing improved vaccine potency and breadth against COVID-19 and HIV in mice.

bioRxiv · Jul 16, 2023 · PreprintBioengineering

A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity

A. A. Rubio, M. V. Filsinger Interrante, B. N. Bell, C. L. Brown, C. C. LaBranche, D. C. Montefiori, P. S. Kim

This paper describes the engineering of a D5 monoclonal antibody variant, D5_AR, which shows enhanced neutralizing activity against tier-2 HIV-1 strains and improved potency in cells expressing FcγRI.

bioRxiv · Oct 23, 2020Immunology

The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat

D. C. Montefiori, M. V. Filsinger Interrante, B. N. Bell, A. A. Rubio, J. G. Joyce, J. W. Shiver, C. C. LaBranche, P. S. Kim

This paper shows that the FcγRI receptor enhances HIV-1 neutralization by NHR-targeting antibodies, enabling neutralization of tier-2 viruses.

bioRxiv · Aug 27, 2020Immunology